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Abstract  
The extraskeletal myxoid chondrosarcoma (CME) is a rare malignant soft tissue tumour described as a distinct clinical, histological, 
immunohistochemical, genetical and evolutive entity. It represents only 2.5% of soft tissue sarcomas. Its individualization is important because it 
has a long and indolent clinical course, and tumour-related death often occurs after a long survival period. The diagnostic key is morphological 
supported by immunohistochemistry and genetics t (9; 22) that allow differentiating it from other tumours with myxoid stroma and from 
chordoma. This report describes a patient with paravertebral extraskeletal myxoid chondrosrcoma with a high locoregional extension. 
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Introduction 
 
Extraskeletal chondrosarcomas were first described by Stout and 
Verner in 1953 [1]; however, it was not until 1972 that extraskeletal 
myxoid chondrosarcoma (EMC) was histopathologically defined as 
its own entity [2]. EMC is provisionally classified as a tumor of 
uncertain differentiation in the revised version of the World Health 
Organization classification of tumors of soft tissue and bone in 2002 
[3]. EMC is a relatively rare but well- characterized tumor [4]. We 




Patient and observation 
 
A 25-year-old female presenting with 3 months history of cauda 
equina syndrome progressively worsening. Lumbar spine medical 
imaging revealed in MRI scan a low signal intensity process on T1 a 
high signal intensity on T2 (Figure 1) and in CT scan a hypodense 
process extending on a height of 7cm and developing in the left 
posterior lumbar soft tissues at the height of L5 extending in the left 
sacral region with infiltration and osteolysis of the sacroiliac joint 
and the left sacral foramina with nerve root compression at this 
level. The patient underwent surgery with resection of a left 
paravertebral lesion + L5 and S1 laminectomy + partial resection of 
the intraductal portion of the tumor. Histopathological study showed 
that the tumor is characterized by multilobular structures divided by 
fibrous septa, and disposed in an abundant myxoid matrix. tumoral 
cells are isolated or grouped in cords, mitoses are rare. Cells 
express the protein S100 and NSE and do not express cytokeratin 
AE1 / AE3 and desmin. Based on these findings, the patient was 
diagnosed with EMC. Postoperative Spinal MRI showed the 
persistence of a large tumor mass of the erector muscles of the 
lumbar spine 68x12mm extending to the gluteal muscles, with 
persistence of the anterior epidural tumoral component and 
extension at lumbosacral spinal (Figure 2). At his admission to the 
department of radiotherapy, 4 weeks later, clinical examination 
found a huge mass in the left buttock and posterior lumbar region. 
Planning CT and CT scanner found an increase in tumor volume 
with the same extensions described in the postoperative imaging in 
addition to extension at the left iliac bone and at the left iliac psoas 
muscle protruding at the left lateral pelvic region. From these 
results, a palliative radiotherapy was delivered in the total dose of 






The CME is a rare entity, distinct clinically, histologically, 
immunohistochemistry, cytogenetics and scalable. It represents 
2.5% of soft tissue sarcomas [5]. Approximately 80% of these 
tumors occur in the extremities, with 20% located in the trunk. The 
lower extremity is the most common location of EMC [4]. The male 
to female ratio of EMC is 2:1, with a peak occurrence in the fifth and 
sixth decades [4]. EMC is a relatively rare neoplasm with no specific 
findings in the clinic. Patients commonly present with non-specific 
symptoms, including tenderness and the detection of a palpable 
mass [3]. The most common manifestation of EMC is an enlarging 
soft tissue mass; some lesions are accompanied by pain and 
tenderness, or may restrict the range of motion. Radiological images 
are not specific; the lesions exhibit low density on CT, low signal 
intensity on T1-weighted MRI scans and high signal intensity on T2-
weighted MRI scans [6]. The tumor ranges from approximately 1-25 
cm (mostly 6-13 cm) in size and usually has a multilobular or 
nodular configuration with a relatively well-defined margin and an 
incomplete fibrous capsule [2,5,7-12]. The cut surface is gray to 
tan-brown and shows a gelatinous appearance, often accompanied 
by intralesional hemorrhage. The tumor is characterized by 
multilobular structures divided by fibrous septa of variable thickness, 
which is a consistent morphological configuration of EMC. Each 
lobule is typically composed of a proliferation of short spindle or 
oval cells arranged in clusters or short anastomosing cords or 
strands, often displaying a lacelike appearance and embedded in an 
abundant myxoid matrix. The tumor cells are generally small and 
have hyperchromatic or vesicular nuclei and eosinophilic or 
sometimes vacuolated cytoplasm. These features are somewhat 
reminiscent of chondroid tissues or lesions. However, the tumor 
usually lacks discernible cartilaginous histology. Mitotic figures are 
rare in most cases [5]. 
  
Immunohistochemically, the cells express vimentin sometimes SNP, 
NSE and PS100 [11,5]. Cytokeratin and EMA are sometimes 
expressed focal manner [11]. Positivity of GFAP was reported. In 
electron microscopy, the presence of parallel microtubules and 
abundant REG are quite characteristic but nonspecific [9,13]. 
Certain studies have shown that they may also be positive for Leu-7 
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and epithelial membrane antigen. Uniformly, they are negative for 
keratin, SMA and desmin [14-16] Genetically, CME is associated in 
about 80% to recurrent specific chromosome translocation t (9; 22) 
(q22; q12), leading to a genetic rearrangement between the EWS 
gene, located on chromosome 22 and the gene TEC, located on 
chromosome 9 [11]. The rearrangement can be searched by RT-
PCR on fixed tissue. Other translocations are rarely observed [5]: t 
(9; 15) (q22; q12), t (9; 17) (q22; q11.2), t (9; 17; 15) (q22; q11 ; 
q22), t (2; 13) (q32; p12) and t (11; 22) (q11; p11) [17]. 
  
EMCS should be distinguished from a variety of myxoid or cartilage-
forming, benign, or malignant, and soft tissue or bone tumors. For 
example, intramuscular myxoma, nerve sheath 
myxoma/neurothekeoma, extraskeletal chondroma, myoepithelioma 
(mixed tumor) of soft parts, parachordoma, metastatic 
adenocarcioma, myxoid liposarcoma, low-grade 
myxofibrosarcoma/myxoid malignant fibrous histiocytoma, 
epithelioid sarcoma, malignant peripheral nerve sheath tumor, and 
extraskeletal or skeletal chondrosarcoma with prominent myxoid 
change. Among them, parachordoma and myoepithelioma of soft 
parts are occasionally difficult to differentiate from EMCS. 
Recognition of the histologic features of conventional EMCS that are 
present, at least in part, is most important for a differential 
diagnosis. Ancillary approaches such as immunohistochemistry and 
electron microscopy are also valuable [5]. Treatment is firstly 
surgery of the initial tumor and / or metastasis, radiotherapy and 
chemotherapy as first-line have not been proven [18]. This tumor 
does not respond to chemotherapy and the results concerning 
radiotherapy are discordant [19]. 
  
The development of CMES is difficult to predict. Nearly half of 
patients have one or more local recurrences within an average of 44 
months [20]. Survival after the onset of metastases is very varied in 
duration, on average 66 months. Although the five-year survival 
rate is quite high, metastases are common (46-90% of cases) and 
long-term prognosis is adverse (30-70% survival at ten years) 
[20,21]. Metastases occur in order of decreasing frequency, in 
lungs, soft tissue, lymph nodes, bone, and brain. The main poor 
prognostic factors are the occurrence in man, the late age of onset, 
tumor size greater than 10 cm, proximal seat, the incompleteness of 
the initial surgical resection, the absence of surgical resection and 
discovery of metastases at diagnosis [11,20]. The histoprognostic 
criteria such as necrosis, mitotic activity, the degree of 
differentiation does not appear to influence the outcome [22]. In 






The CME is a rare entity, distinct clinically, histologically, 
immunohistochemistry, cytogenetics and scalable. The diagnostic 
















Figure 1: Preoperative MRI shows lesion with low signal in T1WI 
and heterogeneous high signal in T2WI 
Figure 2: Postperative MRI shows lesion with low signal in T1WI 
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Figure 1: Preoperative MRI shows lesion with low signal in T1WI and 
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Figure 2: Postperative MRI shows lesion with low signal in T1WI and heterogeneous high signal in T2WI 
 
